• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEW
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SCHEDULE 13G filed by SELLAS Life Sciences Group Inc.

    7/29/25 11:05:52 AM ET
    $SLS
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $SLS alert in real time by email



    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549


    SCHEDULE 13G


    UNDER THE SECURITIES EXCHANGE ACT OF 1934
    SELLAS Life Sciences Group Inc

    (Name of Issuer)


    Common Stock

    (Title of Class of Securities)


    81642T209

    (CUSIP Number)


    06/30/2025

    (Date of Event Which Requires Filing of this Statement)


    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
    Checkbox checked   Rule 13d-1(b)
    Checkbox not checked   Rule 13d-1(c)
    Checkbox not checked   Rule 13d-1(d)






    SCHEDULE 13G

    CUSIP No.
    81642T209


    1Names of Reporting Persons

    The Vanguard Group
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    PENNSYLVANIA
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    92,960.00
    7Sole Dispositive Power

    6,568,778.00
    8Shared Dispositive Power

    126,021.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    6,694,799.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    6.70 %
    12Type of Reporting Person (See Instructions)

    IA

    Comment for Type of Reporting Person:  The holdings reported herein are in the form of warrants.The CUSIP Number listed throughout this filing is the CUSIP assigned to the Ordinary Shares of the Issuer.


    SCHEDULE 13G

    Item 1. 
    (a)Name of issuer:

    SELLAS Life Sciences Group Inc
    (b)Address of issuer's principal executive offices:

    7 TIMES SQUARE, SUITE 2503, NEW YORK, NY, 10036
    Item 2. 
    (a)Name of person filing:

    The Vanguard Group
    (b)Address or principal business office or, if none, residence:

    100 Vanguard Blvd., Malvern, PA 19355
    (c)Citizenship:

    PA
    (d)Title of class of securities:

    Common Stock
    (e)CUSIP No.:

    81642T209
    Item 3.If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
    (a)Checkbox not checked   Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
    (b)Checkbox not checked   Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
    (c)Checkbox not checked   Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
    (d)Checkbox not checked   Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
    (e)Checkbox checked   An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
    (f)Checkbox not checked   An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
    (g)Checkbox not checked   A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
    (h)Checkbox not checked   A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
    (i)Checkbox not checked   A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
    (j)Checkbox not checked   A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J),
           please specify the type of institution:
    (k)Checkbox not checked   Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
     
    Item 4.Ownership
    (a)Amount beneficially owned:

    6694799
    (b)Percent of class:

    6.7  %
    (c)Number of shares as to which the person has:
     (i) Sole power to vote or to direct the vote:

    0

     (ii) Shared power to vote or to direct the vote:

    92960

     (iii) Sole power to dispose or to direct the disposition of:

    6568778

     (iv) Shared power to dispose or to direct the disposition of:

    126021

    Item 5.Ownership of 5 Percent or Less of a Class.
     
    Item 6.Ownership of more than 5 Percent on Behalf of Another Person.
     
    If any other person is known to have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, such securities, a statement to that effect should be included in response to this item and, if such interest relates to more than 5 percent of the class, such person should be identified. A listing of the shareholders of an investment company registered under the Investment Company Act of 1940 or the beneficiaries of employee benefit plan, pension fund or endowment fund is not required.


    The Vanguard Group, Inc.'s clients, including investment companies registered under the Investment Company Act of 1940 and other managed accounts, have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, the securities reported herein. No one other person's interest in the securities reported herein is more than 5%.
    Item 7.Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
     
    Not Applicable
    Item 8.Identification and Classification of Members of the Group.
     
    Not Applicable
    Item 9.Notice of Dissolution of Group.
     
    Not Applicable

    Item 10.Certifications:
     
    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11.

        SIGNATURE 
     
    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     
    The Vanguard Group
     
    Signature:Ashley Grim
    Name/Title:Head of Global Fund Administration
    Date:07/29/2025
    Get the next $SLS alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $SLS

    DatePrice TargetRatingAnalyst
    7/21/2021$18.00Overweight
    Cantor Fitzgerald
    More analyst ratings

    $SLS
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Cantor Fitzgerald initiated coverage on SELLAS Life Sciences with a new price target

    Cantor Fitzgerald initiated coverage of SELLAS Life Sciences with a rating of Overweight and set a new price target of $18.00

    7/21/21 11:28:03 AM ET
    $SLS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    RBC Capital initiated coverage on Solaris Resources with a new price target

    RBC Capital initiated coverage of Solaris Resources with a rating of Outperform and set a new price target of $18.00

    6/21/21 6:52:33 AM ET
    $SLS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $SLS
    SEC Filings

    View All

    SEC Form S-8 filed by SELLAS Life Sciences Group Inc.

    S-8 - SELLAS Life Sciences Group, Inc. (0001390478) (Filer)

    8/12/25 4:38:00 PM ET
    $SLS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SELLAS Life Sciences Group Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    8-K - SELLAS Life Sciences Group, Inc. (0001390478) (Filer)

    8/12/25 4:07:59 PM ET
    $SLS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 10-Q filed by SELLAS Life Sciences Group Inc.

    10-Q - SELLAS Life Sciences Group, Inc. (0001390478) (Filer)

    8/12/25 4:00:58 PM ET
    $SLS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $SLS
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Van Nostrand Robert L bought $14,800 worth of shares (10,000 units at $1.48), increasing direct ownership by 96% to 20,400 units (SEC Form 4)

    4 - SELLAS Life Sciences Group, Inc. (0001390478) (Issuer)

    6/13/25 8:00:33 AM ET
    $SLS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Wasman Jane bought $33,800 worth of shares (20,000 units at $1.69), increasing direct ownership by 192% to 30,400 units (SEC Form 4)

    4 - SELLAS Life Sciences Group, Inc. (0001390478) (Issuer)

    6/2/25 4:42:07 PM ET
    $SLS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Kalin Katherine Bach bought $36,000 worth of shares (20,000 units at $1.80), increasing direct ownership by 95% to 41,000 units (SEC Form 4)

    4 - SELLAS Life Sciences Group, Inc. (0001390478) (Issuer)

    5/22/25 4:05:17 PM ET
    $SLS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $SLS
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    SELLAS Life Sciences Reports Second Quarter 2025 Financial Results and Provides Corporate Update

    - Positive IDMC Recommendation to Continue Pivotal Phase 3 REGAL Trial of Galinpepimut-S (GPS) in AML Without Modification; Final Analysis Anticipated by Year-end 2025 –- Reported Positive Phase 2 Results of SLS009 in Relapsed/Refractory (r/r) Acute Myeloid Leukemia (AML) with Trial Meeting All Primary Endpoints; Full Data Presentation Expected Later This Year -- Alignment with FDA to Advance SLS009 in a First-Line AML Trial with Enrollment Anticipated by Q1 2026 -- $25.3 million in Cash and Cash Equivalents as of June 30, 2025; Additional $4.0 million Proceeds Received in July 2025 for Warrant Exercises - NEW YORK, Aug. 12, 2025 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group, Inc. (NAS

    8/12/25 4:05:00 PM ET
    $SLS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SELLAS Life Sciences Announces Independent Data Monitoring Committee Periodic Review and Positive Recommendation to Continue Pivotal Phase 3 REGAL Trial of GPS in AML Without Modification

    -        Final Analysis Anticipated by Year-End Upon Occurrence of 80 Events        - NEW YORK, Aug. 07, 2025 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group, Inc. (NASDAQ:SLS) ("SELLAS'' or the "Company"), a late-stage clinical biopharmaceutical company focused on the development of novel therapies for a broad range of cancer indications, today announced that the Independent Data Monitoring Committee (IDMC) has completed a pre-specified analysis of the Phase 3 REGAL trial of galinpepimut-S (GPS) in acute myeloid leukemia (AML), and has issued a positive recommendation to continue the trial without modification. The IDMC concluded that the risk-benefit profile of GPS supports cont

    8/7/25 8:30:00 AM ET
    $SLS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SELLAS Meets All Primary Endpoints in Phase 2 Trial of SLS009 in r/r AML and Receives FDA Guidance to Advance into First-Line Therapy Study

    The Trial Exceeded Target Overall Response Rate (ORR) of 20%, with 44% Response Rate Among Patients with Acute Myeloid Leukemia-Myelodysplasia-Related Changes (AML MR) Treated at Optimal Dose of 30 mg Twice a Week (BIW) and 50% in AML MR with Myelomonocytic/Myelomonoblastic (M4/M5) SubtypeMedian Overall Survival (mOS) of 8.9 Months in Patients with AML MR and 8.8 mOS in Relapsed or Refractory to Venetoclax-Based Regimens at 30 mg BIW Dose Level Surpasses the Historical Benchmark of 2.4 MonthsFDA Recommends Advancement towards a Trial Including Newly Diagnosed First-Line AML Patient Cohorts That May Support a New Drug Application; Trial Preparation Underway with Enrollment Expected to Begin b

    7/15/25 7:45:00 AM ET
    $SLS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $SLS
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Van Nostrand Robert L bought $14,800 worth of shares (10,000 units at $1.48), increasing direct ownership by 96% to 20,400 units (SEC Form 4)

    4 - SELLAS Life Sciences Group, Inc. (0001390478) (Issuer)

    6/13/25 8:00:33 AM ET
    $SLS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Wasman Jane bought $33,800 worth of shares (20,000 units at $1.69), increasing direct ownership by 192% to 30,400 units (SEC Form 4)

    4 - SELLAS Life Sciences Group, Inc. (0001390478) (Issuer)

    6/2/25 4:42:07 PM ET
    $SLS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Kalin Katherine Bach bought $36,000 worth of shares (20,000 units at $1.80), increasing direct ownership by 95% to 41,000 units (SEC Form 4)

    4 - SELLAS Life Sciences Group, Inc. (0001390478) (Issuer)

    5/22/25 4:05:17 PM ET
    $SLS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $SLS
    Leadership Updates

    Live Leadership Updates

    View All

    SELLAS Life Sciences Appoints Linghua Wang, MD, PhD, to Scientific Advisory Board

    NEW YORK, July 07, 2025 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group, Inc. (NASDAQ:SLS) ("SELLAS'' or the "Company"), a late-stage clinical biopharmaceutical company focused on the development of novel therapies for a broad range of cancer indications, today announced the addition of Linghua Wang, MD, PhD, to its Scientific Advisory Board (SAB). Dr. Wang is a widely respected leader in cancer research and translational science, and she joins the Company's SAB shortly after the appointments of Philip C. Amrein, MD, and Dr. Alex Kentsis, MD, PhD. "We are thrilled to welcome Dr. Wang to our Scientific Advisory Board," said Dragan Cicic, MD, Senior Vice President, Chief Development Officer

    7/7/25 8:45:00 AM ET
    $SLS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Wall Street Eyes Breakout Cancer Therapies Amid Soaring Drug Prices

    Equity Insider News Commentary Issued on behalf of Oncolytics Biotech Inc. VANCOUVER, BC, June 24, 2025 /PRNewswire/ -- Equity Insider News Commentary – Rising rates of cancer are going to come at a major cost, and it's looking more and more like the solution is going to have to come from the private sector. Recent reports suggest the U.S. government may slash National Cancer Institute (NCI) funding by nearly 40%, while Bloomberg reports growing concern over affordability and access to cancer drugs whose prices are rising sharply. From Wall Street's point of view, the focus needs to shift towards up-and-coming treatments being developed by promising candidates, including from Oncolytics Biot

    6/24/25 12:52:00 PM ET
    $AUTL
    $CATX
    $INDP
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Medical/Dental Instruments
    Biotechnology: Pharmaceutical Preparations

    SELLAS Life Sciences Expands Scientific Advisory Board with Addition of Two World-Renowned Hematology and Oncology Experts

    NEW YORK, June 05, 2025 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group, Inc. (NASDAQ:SLS) ("SELLAS'' or the "Company"), a late-stage clinical biopharmaceutical company focused on the development of novel therapies for a broad range of cancer indications, today announced the appointment of two distinguished oncology leaders to its Scientific Advisory Board (SAB). The new members – Philip C. Amrein, MD, and Alex Kentsis, MD, PhD bring decades of expertise in cancer research, clinical oncology, and translational medicine, further strengthening the company's strategic guidance as it advances its therapeutic pipeline. "We are honored to welcome Drs. Amrein and Kentsis to our Scientific Advisor

    6/5/25 8:45:00 AM ET
    $SLS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $SLS
    Financials

    Live finance-specific insights

    View All

    SELLAS Life Sciences to Host Virtual Investor Symposium on its Lead Asset, Galinpepimut-S, on September 15, 2022

    NEW YORK, Sept. 08, 2022 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group, Inc. (NASDAQ:SLS) ("SELLAS'' or the "Company"), a late-stage clinical biopharmaceutical company focused on the development of novel therapies for a broad range of cancer indications, today reminds the investment community that it will host a virtual investor symposium on its lead asset, galinpepimut-S (GPS), including the potential commercial opportunity for GPS in AML patients. The conference call and webcast will be held on Thursday, September 15, 2022, from 1:00 p.m. to 2:00 p.m. ET featuring remarks from Angelos Stergiou, M.D., Sc.D. h.c., President and Chief Executive Officer, and Robert Francomano, Chief Commer

    9/8/22 8:00:00 AM ET
    $SLS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SELLAS Life Sciences Reports Third Quarter 2021 Financial Results and Provides Business Update

    NEW YORK, Nov. 12, 2021 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group, Inc. (NASDAQ:SLS) ("SELLAS" or the "Company"), a late-stage clinical biopharmaceutical company focused on developing novel cancer immunotherapies for a broad range of indications, today reported its financial results for the quarter ended September 30, 2021 and provided a business update. "During the third quarter of 2021, in addition to continuing to enroll patients in the United States and Europe for our Phase 3 REGAL study of galinpepimut-S (GPS) in acute myeloid leukemia (AML) patients, we also commenced clinical and regulatory preparations for a potential new Phase 2/3 study of GPS in AML patients following a bon

    11/12/21 8:45:00 AM ET
    $SLS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SELLAS Life Sciences Reports Second Quarter 2021 Financial Results and Provides Business Update

    Reported Promising Updated Clinical Data in Ongoing Clinical Trials of Galinpepimut-S (GPS) in Combination with PD-1 Inhibitors for Malignant Pleural Mesothelioma (MPM) and WT1+ Advanced Ovarian Cancer Recently Published Outcomes Data for Acute Myeloid Leukemia (AML) Patients Highlights Continued Unmet Need and Expanded Market Opportunity for GPS Cash Position of $29.9 million as of June 30, 2021 To Host Virtual Investor Symposium on GPS on August 17, 2021 NEW YORK, Aug. 12, 2021 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group, Inc. (NASDAQ:SLS) ("SELLAS" or the "Company"), a late-stage clinical biopharmaceutical company focused on developing novel cancer immunotherapies for a broad ran

    8/12/21 4:22:52 PM ET
    $SLS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $SLS
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by SELLAS Life Sciences Group Inc.

    SC 13G/A - SELLAS Life Sciences Group, Inc. (0001390478) (Subject)

    11/8/24 8:33:00 AM ET
    $SLS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G filed by SELLAS Life Sciences Group Inc.

    SC 13G - SELLAS Life Sciences Group, Inc. (0001390478) (Subject)

    2/7/24 3:01:47 PM ET
    $SLS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G/A filed

    SC 13G/A - SELLAS Life Sciences Group, Inc. (0001390478) (Subject)

    2/16/21 10:08:07 AM ET
    $SLS
    Biotechnology: Pharmaceutical Preparations
    Health Care